drugset / Trial / NCT03899402
Triple Therapy in T1DM
Phase 2/3
Active not recruiting
78 enrolled
State University of New York at Buffalo
Juvenile Diabetes Research Foundation · collabUniversity of Glasgow · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
Timeline
- Start
- 2019-05-01
- Primary completion
- 2026-01-31
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | Oral |
| Subject | Semaglutide | Peptide | 1 mg | Other |
| Background | Insulin | Protein / enzyme biologic | — | Other |